阿糖胞苷联合VDLD方案对难治/复发性急性淋巴细胞白血病儿童的有效性及安全性探究

Efficacy and Safety of Cytarabine Combined with VDLD Regimen in Children with Refractory/Recurrent Acute Lymphoblastic Leukemia

目的:探究阿糖胞苷联合VDLD方案对难治/复发性急性淋巴细胞白血病儿童的有效性及安全性。方法:研究对象选取我院2015年1月~2016年2月期间收治入院的难治性、复发性白血病患儿80例;通过随机数表法,将患儿分为观察组和对照组,每组40例。对照组患儿采用VDLD方案进行化疗,观察组在对照组治疗的基础上联用阿糖胞苷;对比两组患儿的化疗疗效和不良反应发生情况,并比较两组完全缓解患儿的2年无病生存率。结果:对照组患儿总有效率为62.50%,观察组为92.50%,组间差异具有统计学意义(P<0.05)。观察组和对照组患儿均未出现严重不良反应,无患儿合并产生多种不良反应。对照组不良反应的总发生率为20.00%,观察组为15.00%,组间差异无统计学意义(P>0.05)。观察组完全缓解患儿的2年无病生存率为70.37%,对照组完全缓解患儿的2年无病生存率为30.77%,组间差异显著(P<0.05)。结论:相比于单独使用VDLD方案,阿糖胞苷联合VDLD方案对于儿童难治性、复发性急性淋巴细胞白血病具有更好的治疗效果,且具有较高的安全性,值得推广应用。

Objective:To explore the efficacy and safety of cytarabine combined with VDLD regimen in children with refractory/recurrent acute lymphoblastic leukemia.Methods:80 children with refractory and recurrent leukemia admitted to our hospital from January 2015 to February 2016 were included in the research.According to the random number table method,the children were divided into observation group and control group,40 cases in each group.The control group was treated with VDLD regimen,while the observation group was treated with additional cytarabine on that basis.The efficacy and adverse reactions of the two groups were observed and compared.The 2-year disease-free survival rate of children with complete remission was compared between the two groups.Results:The total effective rate was 62.50%in the control group and 92.50%in the observation group(P<0.05).There were no serious adverse reactions or multiple adverse reactions in both groups.The total incidence of adverse reactions was 20.00%in the control group and 15.00%in the observation group(P>0.05).The 2-year disease-free survival rate was 70.37%in the observation group and 30.77%in the control group(P<0.05).Conclusion:Compared with VDLD alone,cytarabine combined with VDLD has better therapeutic effect and higher safety for children with refractory and recurrent acute lymphoblastic leukemia,which is worthy of promotion and application.